Close menu




July 12th, 2022 | 14:09 CEST

Waiting is not an option! BioNTech, MAS Gold, BASF

  • Gold
  • Biotechnology
  • Inflation
Photo credits: pixabay.com

Inflation is rising and rising. In construction, inflation has already reached almost 20%. Even in everyday life, double-digit inflation rates are not far away. At the same time, infection figures are rising, and it is still uncertain whether gas will flow through Nord Stream 1 again in the coming weeks. Given this mixed situation, many investors are asking how they should invest. Because one thing is clear: waiting is not an option - the real return on many asset classes is clearly negative. We take a look at three stocks and check their future prospects.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , MAS Gold Corp. | CA57457A1057 , BASF SE NA O.N. | DE000BASF111

Table of contents:


    BioNTech: Well prepared for the fall

    Whether BioNTech can emerge as the winner of the Corona situation is not yet certain. Since BioNTech has two hot candidates for the upcoming Corona season, the Company is well-positioned. Actually. Experts from the US Food and Drug Administration (FDA), among others, are currently discussing which vaccines should be launched on the market in the fall. The manufacturers offer solutions specifically directed against Omicron or products intended to be effective against both the original type and Omicron. Doses of the first batches of the vaccines are also still in stock. Given the number of possible solutions, experts warn that the logistics surrounding the vaccines could become more complex, and BioNTech's margins could suffer.

    Nevertheless, the chances are good that the vaccine professionals from Mainz will be able to offer exactly what experts are demanding and vaccinators are accepting in the fall. Since the pandemic has shown that a lot can happen and little can be planned, BioNTech could be well-positioned. The stock also looks attractive from a chart perspective. The share is currently fighting its way out of the sideways movement that has lasted since February. However, it remains to be seen whether the breakout will be successful - BioNTech is now an established stock, making big jumps less likely.

    MAS Gold: Is history repeating itself?

    MAS Gold is the opposite of an established value - at least in Europe. The Company is exploring the La Ronge gold belt in Canada's Saskatchewan province. MAS Gold has several promising smaller properties and is developing them in parallel. The plan is to implement a hub-and-spoke model, where a central processing plant reduces costs and creates flexibility. But for these goals to be achieved, the gold in the ground is critical. A few weeks ago, MAS Gold announced drill results from one-third of its winter drill program. Grades ranging from 0.49 g/t to 3.06 g/t came to light. The task of the Company, led by mining legend Jim Engdahl, will now be to further delineate the deposits and get a picture of the high-grade zones.

    MAS Gold's own belief in moving its projects forward is also evidenced by a financing round involving management and company insiders. With the overall market weakening, especially on the financing side, the stock has come under significant pressure despite the recent successful closing of the capital tranche. This "cliffhanger" can be an opportunity for courageous investors: If MAS Gold successfully implements its strategy and the gold market picks up speed in the wake of general uncertainty, current price levels could be promising. The development of inflation and gold during the 1970s could provide guidance. At that time, gold also only got going with a time lag!

    BASF: More fear than hope

    And what about industrial companies? During past crises, investors could always be sure: In the long term, stocks like BASF always get back on track. And today? Today, energy-intensive industries such as chemicals are threatened with collapse. BASF is painstakingly giving itself a sustainable profile, but tens of thousands of precursors from the Ludwigshafen plant still depend on fossil fuels. If contrary to plans, no more gas flows through Nord Stream 1 in two weeks, shares like BASF will likely come under renewed pressure. The Ludwigshafen shares have already fallen by around 16% in the last three months.


    Inflationary pressure and crisis fears are a dangerous mix. One thing is certain: those investors who do nothing will have to accept a loss of purchasing power in any case, and those who invest incorrectly, likewise. One approach could be to focus on companies that suffer little from the energy price shock and may even have a low valuation. One such candidate, albeit a highly speculative one, is MAS Gold. BioNTech also looks interesting at the moment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on September 25th, 2026 | 10:00 CEST

    Get Set for the Next Gold Rally: DRC Gold, Barrick Mining and Newmont in Focus

    • Gold
    • Commodities
    • Africa
    • rally

    Amid persistent inflation concerns and monetary policy turmoil, gold continues to serve as a safe haven and has hit an all-time high this year. Central banks are using weaker prices to make substantial purchases. With gold trading above USD 4,000 per ounce, producers such as Newmont and Barrick Mining are posting record profits. But exploration companies are also worth watching, as these second- and third-tier stocks could offer significant leverage on gold price movements during prolonged bull markets. DRC Gold fits into this category with an exciting gold project in the Democratic Republic of the Congo. Where are the biggest opportunities?

    Read

    Commented by Stefan Feulner on September 25th, 2026 | 08:00 CEST

    Artemis Gold, Desert Gold and i-80 Gold – Gold Rush 2.0 Begins

    • Gold
    • Commodities
    • Africa
    • geopolitics

    Gold has long since evolved from a mere crisis hedge into a strategic asset. Central banks are expanding their holdings, geopolitical tensions are driving the demand for independent reserves, and investors are seeking protection against inflation and currency risks. According to the World Gold Council, 89% of the reserve managers surveyed expect central bank gold holdings to rise over the next twelve months. At the same time, mining supply is responding only slowly despite high prices. This could further intensify the competition for large deposits.

    Read

    Commented by Nico Popp on September 25th, 2026 | 07:50 CEST

    Breakthroughs in Skin Cancer Treatment: New Approaches from Biofrontera and Moderna – Vidac Pharma Faces a Busy Fall

    • Pharma
    • Biotechnology
    • Biotech
    • Cancer
    • Innovations

    For a long time, the treatment of skin cancer and its precancerous stages resembled a makeshift compromise: Doctors used scalpels, froze affected areas, or prescribed aggressive creams that destroyed tissue. It was not uncommon for patients to suffer pain and weeks of delayed wound healing. But a completely new dynamic is currently emerging in the sector. Suddenly, innovations involving light beams, messenger RNA (mRNA), and the metabolic reprogramming of cancer cells are making headlines. We present the latest developments in skin cancer and its precancerous stages. The race for innovation has only just begun.

    Read